13F Holdings
中文EN

CTKB Cytek Biosciences, Inc.

Laboratory Analytical Instruments · Nasdaq · SEC CIK 1831915 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY5.5%
TTM net income YoY-533.4%
TTM EPS YoY-519.7%
Revenue 3-yr CAGR4.3%
Net income 3-yr CAGR—

Margins

Gross margin54.7%
Operating margin-21.1%
Net margin-39.1%
FCF margin-6.5%
EBITDA margin-18.2%

Returns

ROE-23.2%
ROA-17.3%
ROIC (approx.)-12.8%
Asset turnover0.44x

Leverage & solvency

Liabilities / assets28.0%
Debt / equity0.00x
Current ratio4.46x
Interest coverage-562.56x

Cash quality & payout

Operating cash flow / net income0.08x
Accruals ratio-15.9%
Payout ratio—
Capex / revenue3.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$201.49M$200.45M$193.01M$164.04M$2.18M
Cost of revenue$97.03M$89.35M$83.59M$63.06M$48.81M
Gross profit$104.46M$111.11M$109.43M$100.97M$79.14M
R&D expense$36.47M$39.40M$44.15M$34.86M$24.44M
SG&A expense$58.94M$43.11M$43.97M$34.69M$20.84M
Operating income-$40.38M-$20.52M-$27.84M-$1.80M$9.16M
Interest expense$474,000-$5.24M$2.07M$2.57M$1.74M
Pretax income-$29.84M-$5.70M-$15.71M$1.26M$5.94M
Income tax$36.70M$320,000-$3.56M-$1.22M$2.91M
Net income-$66.54M-$6.02M-$12.15M$2.48M$3.03M
EBITDA-$32.80M-$13.31M-$21.80M$688,000$10.40M
EPS (basic)——-0.090.020.00
EPS (diluted)——-0.090.020.00
Weighted avg. shares (diluted)127.75M130.61M135.28M138.56M81.54M
Balance sheet
Cash & equivalents$90.85M$98.75M$167.63M$299.50M$364.62M
Receivables$62.51M$60.59M$55.93M$48.86M$29.76M
Inventory$48.43M$43.89M$60.88M$48.15M$32.17M
Current assets$392.00M$396.45M$392.06M$454.02M$431.73M
PP&E, net$18.01M$17.96M$18.41M$13.68M$5.85M
Goodwill$16.70M$16.66M$16.18M$10.14M$10.14M
Intangibles$16.82M$20.13M$23.08M$4.33M$4.74M
Total assets$461.54M$499.50M$494.46M$519.48M$463.31M
Current liabilities$77.80M$67.66M$56.23M$49.04M$33.18M
Total liabilities$119.80M$103.76M$101.39M$93.93M$57.92M
Shareholders' equity$341.74M$395.74M$393.06M$425.55M$405.38M
Shares outstanding128.55M129.21M130.71M135.37M133.75M
Cash flow statement
Operating cash flow-$4.69M$25.38M$5.28M-$12.23M$4.63M
Capital expenditure$4.08M$3.52M$4.65M$9.75M$4.36M
Free cash flow-$8.77M$21.85M$633,000-$21.98M$266,000
Investing cash flow$10.12M-$82.97M-$93.89M-$55.91M-$20.99M
Financing cash flow-$13.43M-$15.82M-$41.81M$5.51M$213.56M
Depreciation & amortization$7.58M$7.21M$6.05M$2.49M$1.24M
Stock-based compensation$24.59M$26.85M$22.05M$16.59M$6.59M
Share buybacks$15.07M$21.61M$44.15M$0$0

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.